HSE - PCRS

Application Details

HSE Application ID

HSE100084

HTA Number

25068

HTA Link

https://www.ncpe.ie/mirikizumab-omvoh-hta-id-25068/

Drug

mirikizumab

Brand

Omvoh®

Applicant

Eli Lilly

Indication Applied For

Indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Application Date

18/12/2025

Marketing Authorisation Date

12/02/2025

Application Status

Proposal from Applicant Under Review

27/08/2026

Awaiting Proposal from Applicant

19/03/2026

Applicant Meeting Held with CPU

19/03/2026

Rapid Review Completed

18/12/2025

Pricing and Reimbursement Application Complete

18/12/2025

Rapid Review Commissioned

01/12/2025

New Search